Chongqing Pharscin Pharmaceutical Gets China Municipal Drug Approval for Hepatitis, Blood Circulation Drugs

MT Newswires Live2025-09-25

Chongqing Pharscin Pharmaceutical (SHE:002907) obtained municipal drug approval for two products, according to a Thursday filing with the Shenzhen bourse.

Authorities in Chongqing approved the reregistration for its diammonium glycyrrhizinate active pharmaceutical ingredient, which is extracted from licorice.

The drug is indicated for acute and chronic viral hepatitis associated with high alanine aminotransferase levels, the drug company said.

Officials also approved the reregistration of its sodium ferulate injection, which is used to enhance blood circulation in patients with ischemic cardiovascular and cerebrovascular disease, among other conditions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2570663340?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 15:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570663340","market":"hk","top_or_hot":-1,"title":"Chongqing Pharscin Pharmaceutical Gets China Municipal Drug Approval for Hepatitis, Blood Circulation Drugs","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/002907\">Chongqing Pharscin</a> Pharmaceutical (SHE:002907) obtained municipal drug approval for two products, according to a Thursday filing with the Shenzhen bourse.</p><p>Authorities in Chongqing approved the reregistration for its diammonium glycyrrhizinate active pharmaceutical ingredient, which is extracted from licorice.</p><p>The drug is indicated for acute and chronic viral hepatitis associated with high alanine aminotransferase levels, the drug company said.</p><p>Officials also approved the reregistration of its sodium ferulate injection, which is used to enhance blood circulation in patients with ischemic cardiovascular and cerebrovascular disease, among other conditions.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Pharscin Pharmaceutical Gets China Municipal Drug Approval for Hepatitis, Blood Circulation Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Pharscin Pharmaceutical Gets China Municipal Drug Approval for Hepatitis, Blood Circulation Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-25 15:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/002907\">Chongqing Pharscin</a> Pharmaceutical (SHE:002907) obtained municipal drug approval for two products, according to a Thursday filing with the Shenzhen bourse.</p><p>Authorities in Chongqing approved the reregistration for its diammonium glycyrrhizinate active pharmaceutical ingredient, which is extracted from licorice.</p><p>The drug is indicated for acute and chronic viral hepatitis associated with high alanine aminotransferase levels, the drug company said.</p><p>Officials also approved the reregistration of its sodium ferulate injection, which is used to enhance blood circulation in patients with ischemic cardiovascular and cerebrovascular disease, among other conditions.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2570663340","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570663340","pubTimestamp":1758784437,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chongqing Pharscin Pharmaceutical  obtained municipal drug approval for two products, according to a Thursday filing with the Shenzhen bourse.Authorities in Chongqing approved the reregistration for its diammonium glycyrrhizinate active pharmaceutical ingredient, which is extracted from licorice.The drug is indicated for acute and chronic viral hepatitis associated with high alanine aminotransferase levels, the drug company said.Officials also approved the reregistration of its sodium ferulate injection, which is used to enhance blood circulation in patients with ischemic cardiovascular and cerebrovascular disease, among other conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","002907":"华森制药"},"translate_title":"重庆Pharscin Pharmaceutical获得中国肝炎、血液循环药物市级药品批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002907":0.9},"content_text":"Chongqing Pharscin Pharmaceutical (SHE:002907) obtained municipal drug approval for two products, according to a Thursday filing with the Shenzhen bourse.Authorities in Chongqing approved the reregistration for its diammonium glycyrrhizinate active pharmaceutical ingredient, which is extracted from licorice.The drug is indicated for acute and chronic viral hepatitis associated with high alanine aminotransferase levels, the drug company said.Officials also approved the reregistration of its sodium ferulate injection, which is used to enhance blood circulation in patients with ischemic cardiovascular and cerebrovascular disease, among other conditions.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2570663340","isCrawlerRequest":true}